OBJECTIVE: To study the efficacy and safety of single intravenous bolus administration of indigenously developed tenecteplase (TNK-tPA) in the management of patients with ST-elevation myocardial infarction (STEMI) in clinical practice. METHODS: Observational, prescription-event monitoring study. RESULTS: Data of 15,222 patients who had STEMI and received weight adjusted TNK injection was analyzed. Overall 95.43% patients had clinically successful thrombolysis (CST). In the different subgroups, hypertensives, diabetics, smokers and hyperlipidemic patients had CST rates comparable to the general patient data. CST rates were significantly lower in the elderly patients (>70 years; 92.11%; p < 0.0001), in patients with history of Ischemic Heart Disease (IHD, 93.86%; p = 0.0004) and in patients receiving delayed treatment (>6 h after onset of chest pain; 85.38%; p < 0.0001). CST was significantly higher in patients who received an early thrombolysis (<3 h after onset of chest pain; 96.54%; p = 0.006). Overall mortality was 1.69%, while it was significantly higher in the elderly (4.42%), patients with history of IHD (2.67%), females (2.93%) and in those who received delayed treatment (4.98%). The overall incidences of intracranial hemorrhage (ICH), bleeding excluding ICH, stroke and ventricular tachyarrhythmia were 0.39%, 2.01%, 0.16% and 2.35% respectively. Age >70 years, diabetes, hyperlipidemia and history of IHD were associated with a higher incidence of heart failure, myocardial re-infarction or ventricular tachyarrhythmias. However, incidence of ICH and bleeding other than ICH was comparable amongst all patient subgroups. CONCLUSION: This study confirms the safety and efficacy of indigenous tenecteplase in Indian patients with STEMI, including high risk subgroups. It also highlights the fact that delayed treatment denotes denial of benefits of pharmacologic reperfusion therapy.
OBJECTIVE: To study the efficacy and safety of single intravenous bolus administration of indigenously developed tenecteplase (TNK-tPA) in the management of patients with ST-elevation myocardial infarction (STEMI) in clinical practice. METHODS: Observational, prescription-event monitoring study. RESULTS: Data of 15,222 patients who had STEMI and received weight adjusted TNK injection was analyzed. Overall 95.43% patients had clinically successful thrombolysis (CST). In the different subgroups, hypertensives, diabetics, smokers and hyperlipidemic patients had CST rates comparable to the general patient data. CST rates were significantly lower in the elderly patients (>70 years; 92.11%; p < 0.0001), in patients with history of Ischemic Heart Disease (IHD, 93.86%; p = 0.0004) and in patients receiving delayed treatment (>6 h after onset of chest pain; 85.38%; p < 0.0001). CST was significantly higher in patients who received an early thrombolysis (<3 h after onset of chest pain; 96.54%; p = 0.006). Overall mortality was 1.69%, while it was significantly higher in the elderly (4.42%), patients with history of IHD (2.67%), females (2.93%) and in those who received delayed treatment (4.98%). The overall incidences of intracranial hemorrhage (ICH), bleeding excluding ICH, stroke and ventricular tachyarrhythmia were 0.39%, 2.01%, 0.16% and 2.35% respectively. Age >70 years, diabetes, hyperlipidemia and history of IHD were associated with a higher incidence of heart failure, myocardial re-infarction or ventricular tachyarrhythmias. However, incidence of ICH and bleeding other than ICH was comparable amongst all patient subgroups. CONCLUSION: This study confirms the safety and efficacy of indigenous tenecteplase in Indian patients with STEMI, including high risk subgroups. It also highlights the fact that delayed treatment denotes denial of benefits of pharmacologic reperfusion therapy.
Authors: Christian Juhl Terkelsen; Lisette Okkels Jensen; Hans-Henrik Tilsted; Sven Trautner; Søren Paaske Johnsen; Werner Vach; Hans Erik Bøtker; Leif Thuesen; Jens Flensted Lassen Journal: Ann Intern Med Date: 2011-09-20 Impact factor: 25.391
Authors: Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Hoa L Nguyen; Jane S Saczynski; Joel M Gore; Molly E Waring; Darleen Lessard; Jorge Yarzebski; George Reed; Frederick A Spencer; Shu-xia Li; Robert J Goldberg Journal: Am J Med Date: 2011-10 Impact factor: 4.965
Authors: F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White Journal: Lancet Date: 1999-08-28 Impact factor: 79.321
Authors: Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Warren J Cantor; David Fitchett; Bjug Borgundvaag; John Ducas; Michael Heffernan; Eric A Cohen; Laurie J Morrison; Anatoly Langer; Vladimir Dzavik; Shamir R Mehta; Charles Lazzam; Brian Schwartz; Amparo Casanova; Shaun G Goodman Journal: N Engl J Med Date: 2009-06-25 Impact factor: 91.245
Authors: Tami L Bair; Joseph B Muhlestein; Heidi T May; Kent G Meredith; Benjamin D Horne; Robert R Pearson; Qunyu Li; Kurt R Jensen; Jeffrey L Anderson; Donald L Lappé Journal: Circulation Date: 2007-09-11 Impact factor: 29.690
Authors: Paul W Armstrong; Anthony H Gershlick; Patrick Goldstein; Robert Wilcox; Thierry Danays; Yves Lambert; Vitaly Sulimov; Fernando Rosell Ortiz; Miodrag Ostojic; Robert C Welsh; Antonio C Carvalho; John Nanas; Hans-Richard Arntz; Sigrun Halvorsen; Kurt Huber; Stefan Grajek; Claudio Fresco; Erich Bluhmki; Anne Regelin; Katleen Vandenberghe; Kris Bogaerts; Frans Van de Werf Journal: N Engl J Med Date: 2013-03-10 Impact factor: 176.079